How Much Does Zepbound Cost in Wisconsin in 2026?

Retail and List Pricing in Wisconsin

The manufacturer list price for Zepbound is $1,059.87 per month across all dose strengths, set by Eli Lilly. This figure applies nationally and does not vary by state. Wisconsin retail pharmacies, including chains like Walgreens, CVS, and independent locations, generally charge this same amount to uninsured or cash-pay patients.

Zepbound received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity. The drug is a dual GIP/GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. Doses start at 2.5 mg and titrate upward to a maximum of 15 mg over a minimum of 20 weeks.

Price does not change with dose. Whether a patient fills the 2.5 mg starter pen or the 15 mg maintenance pen, Lilly's wholesale acquisition cost remains the same. Wisconsin has no state-level drug price cap or discount mandate that alters this figure for commercial sales.

In the SURMOUNT-1 trial (N=2,539), participants on tirzepatide 15 mg achieved 22.5% mean body weight reduction at 72 weeks compared with 3.1% for placebo [1]. That level of efficacy drives demand, but the price point creates a real access barrier for many Wisconsin residents.

Wisconsin Medicaid Coverage

Wisconsin Medicaid covers Zepbound with prior authorization. This means BadgerCare Plus members and other Medicaid-enrolled adults can access the medication, but the prescriber must submit documentation showing the patient meets specific clinical criteria before the pharmacy will fill it.

Typical prior authorization requirements include a confirmed BMI of 30 or greater (or 27+ with a qualifying comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), documented failure of lifestyle interventions, and a treatment plan signed by a licensed prescriber. The Wisconsin Department of Health Services Preferred Drug List determines whether Zepbound sits on a preferred or non-preferred tier, which affects whether a step-therapy requirement applies.

Processing time for Medicaid PA in Wisconsin usually takes 24 to 72 hours. Some managed care organizations (MCOs) that administer BadgerCare Plus, such as Quartz, Molina Healthcare, and Dean Health Plan, may have slightly different formulary positions. Patients should verify coverage with their specific MCO before assuming approval.

According to the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity, GLP-1 and dual GIP/GLP-1 receptor agonists are recommended as first-line pharmacotherapy when lifestyle modification alone is insufficient [2]. This guideline language strengthens PA approval odds because it establishes tirzepatide as a guideline-concordant therapy rather than an experimental option.

Commercial Insurance Coverage

Which private insurers cover Zepbound in Wisconsin? The answer depends on the specific plan, employer, and formulary year. Several major carriers operating in the state have added anti-obesity medications to their formularies, though coverage remains inconsistent.

Plans more likely to cover Zepbound in Wisconsin:

• UnitedHealthcare: Select employer-sponsored plans include GLP-1 coverage for weight management. Members should check their Summary of Benefits for "anti-obesity medication" language.
• Anthem Blue Cross Blue Shield: Some Wisconsin large-group plans cover Zepbound on a specialty tier with PA.
• Quartz Health Solutions: Certain HMO and POS products list tirzepatide for weight management.

Common exclusions to watch for:

Many self-insured employer plans in Wisconsin still carry blanket "weight loss medication" exclusions. These exclusions predate the newer obesity pharmacotherapy approvals and may not reflect updated clinical evidence. Patients denied coverage should request the specific exclusion language in writing and consider filing an internal appeal citing the American Association of Clinical Endocrinology (AACE) consensus statement on obesity [3].

A 2023 KFF employer survey found that only 44% of large firms offering health benefits covered GLP-1 receptor agonists for weight loss [4]. Wisconsin mirrors this national pattern. The percentage is rising year over year, but gaps remain wide.

The Eli Lilly Savings Card

Eli Lilly offers a manufacturer savings card for Zepbound that can reduce out-of-pocket costs to $25 per month for commercially insured patients. The card is not valid for Medicare, Medicaid, Tricare, or other government-funded insurance.

How it works: the savings card covers the difference between a patient's copay or coinsurance and $25, up to a maximum benefit of $563 per monthly fill. If the plan's cost-sharing exceeds $563, the patient pays the remainder. Wisconsin patients with commercial coverage and a copay under $563 will effectively pay $25 per fill.

Eligibility requires a valid prescription, commercial insurance that covers Zepbound (even partially), and U.S. Residency. The card resets annually. Patients can enroll at Lilly's Zepbound website or receive an activation code from their prescriber's office.

For patients whose insurance does not cover Zepbound at all, Lilly launched the LillyDirect program, which offers single-dose vials at $549 per month shipped directly to the patient. This is lower than the $1,059 list price but still represents a significant monthly expense. The vials require the patient to use a syringe rather than the auto-injector pen.

Compounded Tirzepatide in Wisconsin

Compounded tirzepatide is available in Wisconsin through licensed 503A compounding pharmacies at approximately $249 per month. This represents a 76% savings compared to the brand-name list price.

Wisconsin follows federal law governing 503A compounding under the Drug Quality and Security Act (DQCA). A 503A pharmacy can compound tirzepatide for an individual patient based on a valid prescription from a licensed prescriber, provided the compounded product is not "essentially a copy" of an FDA-approved drug that is commercially available. The FDA's current shortage list has included tirzepatide at various points, which affects compounding legality.

Key considerations for Wisconsin patients exploring compounded tirzepatide:

Legality. When tirzepatide appears on the FDA drug shortage list, 503A pharmacies can legally compound it. If the shortage resolves, compounding rights narrow. Wisconsin does not have a state-level statute that independently authorizes compounding beyond federal rules. Patients should confirm the current shortage status before each refill.

Quality. Not all compounding pharmacies are equal. Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation or state inspection records from the Wisconsin Pharmacy Examining Board. Ask the pharmacy whether they perform potency and sterility testing on each batch.

Dose accuracy. Brand-name Zepbound pens deliver a precise, fixed dose. Compounded tirzepatide from vials requires the patient or provider to draw the correct volume with a syringe. Dosing errors are possible, particularly during titration.

Dr. Robert Kushner, a professor of medicine at Northwestern University and an investigator on the SURMOUNT trials, has noted: "The efficacy and safety data we have for tirzepatide come from the branded, FDA-approved formulation. Compounded versions have not undergone the same rigorous testing, and patients should understand that tradeoff" [5].

Telehealth Access in Wisconsin

Wisconsin allows telehealth prescribing of Zepbound. Patients can receive an initial evaluation and prescription from a licensed provider via video or audio visit without an in-person exam, provided the prescriber holds a valid Wisconsin medical license or has an interstate compact privilege.

This is a meaningful access point. Patients in rural parts of Wisconsin, including areas of northern and western Wisconsin where obesity medicine specialists are scarce, can connect with prescribers in Milwaukee, Madison, or even out-of-state clinicians licensed in Wisconsin. Several national telehealth platforms now operate in the state, offering weight management programs that include tirzepatide prescribing, lab monitoring, and ongoing dose titration.

Wisconsin enacted telehealth parity legislation requiring commercial insurers to reimburse telehealth visits at the same rate as in-person visits for the same service. This means the consultation itself should be covered at standard rates, though the medication coverage depends on the plan's formulary.

Wisconsin Medicaid also covers telehealth visits for obesity management. A patient could complete their entire Zepbound journey, from the initial evaluation to ongoing monthly check-ins, without visiting a clinic in person.

How to Minimize Your Zepbound Cost in Wisconsin

The path to the lowest price depends on your insurance status. Here is a decision framework ranked by typical monthly out-of-pocket cost:

If you have commercial insurance that covers Zepbound: Apply the Lilly savings card. Expected cost: $25 per month.

If you have Wisconsin Medicaid (BadgerCare Plus): Ask your prescriber to submit PA. Expected cost: $0 to $3 per fill (Medicaid copay).

If you have commercial insurance that excludes weight-loss drugs: File an appeal. If denied, consider LillyDirect single-dose vials at $549 per month, or compounded tirzepatide at roughly $249 per month through a licensed 503A pharmacy.

If you are uninsured: Compounded tirzepatide at $249 per month is typically the lowest-cost option. LillyDirect vials at $549 per month offer a branded alternative. Eli Lilly's patient assistance program may provide free medication to qualifying low-income patients; income thresholds and application details are available at Lilly's website.

A study published in JAMA Network Open found that out-of-pocket costs exceeding $50 per month for anti-obesity medications were associated with a 40% to 60% drop in 12-month adherence [6]. Keeping costs low is not just a financial concern. It directly affects whether the drug works, because tirzepatide requires consistent weekly dosing to maintain its metabolic effects.

Clinical Efficacy: What Wisconsin Patients Can Expect

Zepbound's clinical profile is well established through the SURMOUNT trial program. The data give Wisconsin patients and prescribers a clear picture of expected outcomes.

In SURMOUNT-1, adults without type 2 diabetes treated with tirzepatide 15 mg lost a mean of 22.5% of body weight at 72 weeks, compared with 3.1% for placebo (P<0.001) [1]. Participants on the 10 mg dose lost 19.5%, and those on 5 mg lost 15.0%. Over one-third of participants in the 15 mg group achieved 25% or greater weight loss.

SURMOUNT-2 studied tirzepatide in adults with type 2 diabetes and obesity. Mean weight loss reached 14.7% with the 15 mg dose at 72 weeks [7]. The drug also improved A1C, blood pressure, and lipid parameters.

The most common side effects are gastrointestinal: nausea (affecting roughly 25% to 33% of patients in trials), diarrhea, constipation, and decreased appetite. These effects are typically mild to moderate and tend to diminish after the first 8 to 12 weeks of treatment. Slow dose titration, as specified in the FDA prescribing information, reduces the severity of GI symptoms [8].

The Endocrine Society recommends that patients on tirzepatide receive monitoring of heart rate, renal function, and gallbladder symptoms, in addition to standard metabolic labs, during the first year of treatment [2].

Wisconsin-Specific Considerations

Wisconsin's healthcare market has features that affect Zepbound access in ways that differ from neighboring states.

Employer field. Wisconsin has a high concentration of self-insured employers, particularly in manufacturing and healthcare sectors. Self-insured plans are regulated under ERISA (federal law), not state insurance mandates. This means Wisconsin cannot require these plans to cover anti-obesity medications even if the state passed a coverage mandate. Employees of large self-insured Wisconsin employers like Epic Systems, Oshkosh Corporation, or Kohl's should check their specific plan documents rather than assuming state-level rules apply.

Pharmacy access. Wisconsin has 1,200+ licensed retail pharmacies. Zepbound is stocked at most chain locations. Specialty pharmacies like Accredo and OptumRx handle mail-order fulfillment for plans that require specialty distribution.

Provider density. The Wisconsin chapter of the Obesity Medicine Association lists board-certified obesity medicine physicians in Madison, Milwaukee, Green Bay, and Appleton. Patients outside these metro areas can use telehealth to access these specialists.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has stated: "Geographic access to obesity medicine specialists should not determine whether a patient receives evidence-based pharmacotherapy. Telehealth has been one of the most meaningful policy changes for weight management in rural states" [9].

What Happens if You Stop Zepbound

Weight regain after discontinuation is a clinical reality. The SURMOUNT-4 trial showed that participants who stopped tirzepatide after 36 weeks of treatment regained approximately 14 percentage points of body weight over the subsequent 52 weeks, while those who continued treatment maintained their losses [10]. This finding has direct cost implications for Wisconsin patients: stopping and restarting the drug because of insurance lapses or cost barriers may reduce long-term benefit.

Wisconsin patients considering Zepbound should plan for sustained use. The Endocrine Society's 2024 guideline describes obesity as a chronic disease requiring ongoing pharmacotherapy in most cases, similar to hypertension or type 2 diabetes [2]. A 72-week treatment course at $25 per month (with the savings card) totals $450. The same course at the $1,059 list price totals $19,062. The gap between those figures underscores why insurance coverage and discount programs are not optional extras but clinical necessities.

Patients filling Zepbound at Wisconsin pharmacies should confirm their savings card enrollment, Medicaid PA status, or compounding pharmacy accreditation before each refill cycle to avoid gaps in therapy.